This article was originally published in The Gray Sheet
Executive SummaryPublished in the March issue of Cancer, the journal of the American Cancer Society, finds that 25 of 55 patients with chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome responded to treatment with the Imre Prosorba immunoadsorption column. Of the patients who responded, 61% had an "estimated one-year survival rate." Only 22% of patients who did not respond to the Prosorba therapy demonstrated a one-year survival rate. In the study, Harry Snyder, PhD, Imre Corporation, et al. find "protein A immunoadsorption...an effective and safe treatment for cancer chemotherapy-associated TTP/HUS".
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.